Neurocrine Bio. (NBIX) PT Lowered to $128 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $128.00 (from $142.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
